Literature DB >> 7581361

Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice.

S F Phelps1, M A Hauser, N M Cole, J A Rafael, R T Hinkle, J A Faulkner, J S Chamberlain.   

Abstract

Duchenne and Becker muscular dystrophy are caused by defects in the dystrophin gene, and are candidates for treatment by gene therapy. We have shown previously that overexpression of a full-length dystrophin cDNA prevents the development of dystrophic symptoms in mdx mice. We show here that this functional correction can be achieved by expressing the full-length muscle isoform at a lower level than is present in control animals. Gene therapy for DMD may necessitate the use of truncated dystrophin mini-genes to accommodate the limited cloning capacity of current-generation viral delivery vectors. We have constructed both murine and human mini-genes deleted for exons 17-48, and have demonstrated that expression of either mini-gene can almost completely prevent the development of dystrophic symptoms in transgenic mdx mice. These results suggest that viral-mediated expression of moderate levels of a truncated dystrophin could be an effective treatment for DMD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7581361     DOI: 10.1093/hmg/4.8.1251

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  93 in total

Review 1.  Correction of genetic disease by making sense from nonsense.

Authors:  R J Kaufman
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

2.  Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation.

Authors:  Davin M Henderson; Ann Lee; James M Ervasti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

3.  Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.

Authors:  Paul S Sharp; Hema Bye-a-Jee; Dominic J Wells
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

4.  Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

Authors:  Paul Gregorevic; Michael J Blankinship; James M Allen; Robert W Crawford; Leonard Meuse; Daniel G Miller; David W Russell; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2004-07-25       Impact factor: 53.440

5.  Impacts of dystrophin and utrophin domains on actin structural dynamics: implications for therapeutic design.

Authors:  Ava Yun Lin; Ewa Prochniewicz; Davin M Henderson; Bin Li; James M Ervasti; David D Thomas
Journal:  J Mol Biol       Date:  2012-04-11       Impact factor: 5.469

6.  Truncated dystrophins can influence neuromuscular synapse structure.

Authors:  Glen B Banks; Jeffrey S Chamberlain; Stanley C Froehner
Journal:  Mol Cell Neurosci       Date:  2009-01-08       Impact factor: 4.314

7.  Full-length dystrophin reconstitution with adeno-associated viral vectors.

Authors:  William Lostal; Kasun Kodippili; Yongping Yue; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2014-03-31       Impact factor: 5.695

8.  Mini-dystrophin restores L-type calcium currents in skeletal muscle of transgenic mdx mice.

Authors:  O Friedrich; M Both; J M Gillis; J S Chamberlain; R H A Fink
Journal:  J Physiol       Date:  2003-10-31       Impact factor: 5.182

Review 9.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

10.  A marginal level of dystrophin partially ameliorates hindlimb muscle passive mechanical properties in dystrophin-null mice.

Authors:  Chady H Hakim; Dongsheng Duan
Journal:  Muscle Nerve       Date:  2012-12       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.